Thromb Haemost 1994; 72(04): 645-646
DOI: 10.1055/s-0038-1648930
Letter to the Editor
Schattauer GmbH Stuttgart

Influence of Lupus Anticoagulant on a Commercially Available Kit for APC-Resistance

W-M Halbmayer
Central Laboratory, Municipal Hospital Vienna-Lainz, Vienna, Austria
,
A Haushofer
Central Laboratory, Municipal Hospital Vienna-Lainz, Vienna, Austria
,
R Schön
Central Laboratory, Municipal Hospital Vienna-Lainz, Vienna, Austria
,
M Fischer
Central Laboratory, Municipal Hospital Vienna-Lainz, Vienna, Austria
› Author Affiliations
Further Information

Publication History

Received 24 March 1994

Accepted after resubmission 15 June 1994

Publication Date:
06 July 2018 (online)

 
  • References

  • 1 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
  • 2 Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-1400
  • 3 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-522
  • 4 Halbmayer W-M, Haushofer A, Schön R, Fischer M. The prevalence of poor anticoagulant response to activated protein C (APC-resistance) among patients suffering from stroke or venous thrombosis and among healthy subjects. Blood Coag Fibrinolysis 1994; 5: 51-57
  • 5 Melichart M, Hauser I, Kyrle A, Lechner K, Pabinger I. Prevalence and clinical features of protein C cofactor deficiency in 150 patients with a history of venous thromboembolism. Ann Hematol 1994; 68 (Suppl. 02) A 66
  • 6 Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-1993
  • 7 Koster T, Rosendaal FR, de Ronde J, Briët E, Vanderbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-1506
  • 8 Faioni EM, Franchi F, Asti D, Sacchi E, Bemardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-1071
  • 9 Moritz B, Halbmayer W-M, Lang H, Fischer M. Possible interaction of APC-response on clotting protein S assays. Ann Hematol 1994; 68 S. II: A112
  • 10 Rosén S, Johansson K, Lindberg K, Dahlbäck B. and the APC-Resistance Study Group. Multicenter evaluation of a kit for activated protein C resistance on various coagulation instruments using plasmas from healthy individuals. Thromb Haemost 1994; 72: 255-260
  • 11 Halbmayer W-M, Haushofer A, Schratzberger W, Petera P, Duschet P, Fischer M. Assessment of lupus anticoagulants within the routine coagulation laboratory - Evaluation of 36 patients suffering from systemic lupus erythematosus. Med Klinik 1993; 88: 417-422
  • 12 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
  • 13 Lindblad B, Svensson PJ, Dahlbäck B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet 1994; 343: 917